Milestone Pharmaceuticals (MIST) Stock Price, News & Analysis

Company Overview

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Key Stats

• Today's Range: $1.75 to $2.01
• 50-Day Range: $1.39 to $1.95
• 52-Week Range: $1.12 to $3.52
• Volume: 521,949 shs
• Average Volume: 221,924 shs
• Market Capitalization: $98.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Buy

Milestone Pharmaceuticals Stock Analysis - MarketRank™

Milestone Pharmaceuticals scored higher than 38% of companies evaluated by MarketBeat, and ranked 733rd out of 974 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Milestone Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Milestone Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Milestone Pharmaceuticals are expected to decrease in the coming year, from ($0.71) to ($1.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Milestone Pharmaceuticals is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Milestone Pharmaceuticals is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Milestone Pharmaceuticals has a P/B Ratio of 3.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.84% of the outstanding shares of Milestone Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Milestone Pharmaceuticals has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Milestone Pharmaceuticals has recently increased by 2.91%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Milestone Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Milestone Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.84% of the outstanding shares of Milestone Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Milestone Pharmaceuticals has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Milestone Pharmaceuticals has recently increased by 2.91%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Milestone Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for MIST on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

2 people have added Milestone Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Milestone Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.90% of the stock of Milestone Pharmaceuticals is held by insiders.

Percentage Held by Institutions

86.18% of the stock of Milestone Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MIST Stock Analysis - Frequently Asked Questions

How have MIST shares performed this year?

Milestone Pharmaceuticals' stock was trading at $1.67 on January 1st, 2024. Since then, MIST stock has increased by 10.5% and is now trading at $1.8450.
View the best growth stocks for 2024 here.

How were Milestone Pharmaceuticals' earnings last quarter?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) released its quarterly earnings results on Thursday, August, 8th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.05.

When did Milestone Pharmaceuticals IPO?

Milestone Pharmaceuticals (MIST) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Who are Milestone Pharmaceuticals' major shareholders?

Milestone Pharmaceuticals' top institutional shareholders include BML Capital Management LLC (2.13%), Atria Investments Inc (0.08%) and Valeo Financial Advisors LLC (0.04%). Insiders that own company stock include Rtw Investments, Lp, Paul F Truex, Robert James Wills, David Bharucha and Debra K Liebert.
View institutional ownership trends.

How do I buy shares of Milestone Pharmaceuticals?

Shares of MIST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Milestone Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Milestone Pharmaceuticals investors own include OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Tilray (TLRY), VBI Vaccines (VBIV), CymaBay Therapeutics (CBAY), Vaxart (VXRT) and Aquestive Therapeutics (AQST).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 11/08/2024
• Next Earnings (Estimated): 11/11/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MIST
• CUSIP: N/A
• CIK: 1408443
• Web: www.milestonepharma.com
• Phone: (514) 336-0444
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.00
• High Stock Price Target: $25.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +550.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-59,690,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -165.26%
• Return on Assets: -55.71%

Debt

• Debt-to-Equity Ratio: 1.61
• Current Ratio: 19.13
• Quick Ratio: 19.13

Sales & Book Value

• Annual Sales: $1 million
• Price / Sales: 98.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.50 per share
• Price / Book: 3.69

Miscellaneous

• Outstanding Shares: 53,270,000
• Free Float: 47,996,000
• Market Cap: $98.28 million
• Optionable: Optionable
• Beta: 1.72